The phase II clinical trial NCT04847466 (Table 1), referred above, is currently recruiting patients with recurrent/metastatic gastric or head and neck cancer, to test PD-L1 CAR-NK in combination with Pembrolizumab, together with an IL-15 superagonist. Here, CD274 is linked to head and neck cancer.